{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By PETER J. HENNING", "person": [{"middlename": "J.", "firstname": "Peter", "role": "reported", "lastname": "HENNING", "rank": 1, "organization": ""}]}, "abstract": null, "type_of_material": "News", "word_count": "1084", "keywords": [{"rank": "1", "value": "United States Politics and Government", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Racketeering and Racketeers", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Insys Therapeutics Inc", "is_major": "N", "name": "organizations"}, {"rank": "4", "value": "Justice Department", "is_major": "N", "name": "organizations"}, {"rank": "5", "value": "Babich, Michael L", "is_major": "N", "name": "persons"}, {"rank": "6", "value": "Sessions, Jefferson B III", "is_major": "N", "name": "persons"}], "lead_paragraph": "The Justice Department\u2019s use of an anti-racketeering law in a health care fraud case might portend more aggressive crackdowns on executives.", "pub_date": "2016-12-12T22:20:34+0000", "document_type": "article", "source": "The New York Times", "snippet": "The Justice Department\u2019s use of an anti-racketeering law in a health care fraud case might portend more aggressive crackdowns on executives....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-thumbWide.jpg"}, {"height": 416, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "416", "xlarge": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/12/13/business/13DB-WHITECOLLAR/13DB-WHITECOLLAR-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/12/12/business/dealbook/rico-charge-in-pharmaceutical-case-may-signal-tougher-tactics.html", "slideshow_credits": null, "blog": [], "_id": "584f22b995d0e03926075989", "headline": {"main": "RICO Charge in Pharmaceutical Case May Signal Tougher Tactics", "content_kicker": "White Collar Watch", "kicker": "White Collar Watch"}}